ClinicalTrials.gg
RecruitingNCT06822426Updated Sep 25, 2026

Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)

A Phase 3 interventional study of (taurolidine and heparin) catheter lock solution and Heparin in Central Line Associated Blood Stream Infections (CLABSI), sponsored by CorMedix Therapeutics. Recruiting at 24 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by CorMedix Therapeutics · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Sep 25, 2026Eligibility revisedPrimary outcomes revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult and adolescent participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.

02

Conditions studied

  • Central Line Associated Blood Stream Infections (CLABSI)
03

In context

Lead sponsor

CorMedix Therapeutics is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Sep 25, 2026. See what changed

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Participants who are resident within study site's country.
  2. Participants who are male or female, aged ≥12 years at the time of consent.
  3. Participants must sign and provide . For adolescent participants or participants that require a legal representative, written informed consent will be obtained from the study participant's legal guardian or legal representative and the assent from the participant when applicable. All legal guardians and representatives should be fully informed, and participants should be informed to the fullest extent possible about the study using language and terms they are able to understand.
  4. Participants who have a tunneled/non-tunneled CVC or peripherally inserted central catheter (PICC) made of silicone or polyurethane, which has been in place for at least 7 days prior to enrollment.
  5. Participants who require long-term (>3 Months) TPN based on the investigator assessments.
  6. Participants who require TPN for at least 3 days per week, of which 2 days have to be parenteral nutrition (PN).
  7. Participants who have a minimum of a 4-hour CLS dwelling time and are willing to lock all lumens at a minimum of every 7 days.
  8. Participants who are clinically stable, in the opinion of the investigator, for at least 4 weeks prior to enrollment.
  9. Participants who are able and willing to be trained or have a caregiver who is willing and able to be trained on the instillation, aspiration of DefenCath or heparin, and to maintain a daily diary.

    Male or female participants:

  10. Women of (WOCBP; see Section 4.5.1) must have a negative pregnancy test at screening (i.e., the participant is not pregnant); not be lactating; and use an acceptable method of including but not limited to, abstinence, bilateral tubal ligation, vasectomized partner, a barrier method (diaphragm or condom), Depo-Provera, intrauterine device, or hormonal contraceptive (oral, implant, ring, patch) for the duration of the program until at least 30 days after the last DefenCath CLS instillation. (NOTE: The participant must have used the chosen method of birth control for at least 1 month/cycle prior to enrollment into the study).
  11. Male participants who are sexually active with a female partner of childbearing potential must agree to use male condoms with spermicide, even if the male participant has undergone a successful vasectomy (males with vasectomy can use condoms without spermicide), from Day 1 until at least 30 days after the last DefenCath CLS instillation.
  12. Participants who comply with all study procedures and follow-up evaluations.

Exclusion Criteria:

  1. Any participant unable or not willing to sign inform consent or, in the case of adolescents, not willing to provide assent.
  2. Any participant who is currently receiving systemic antibiotics. Topical antibiotics are permitted. Use of metronidazole or rifaximin for treating small intestinal bacterial overgrowth (SIBO) is also permitted.
  3. Any participant with visible evidence of compromised skin integrity present at the catheter exist site or catheter exit site infection.
  4. Any participant with a secondary CVC in addition to the primary TPN line.
  5. Any participant that has received thrombolytic treatment (e.g., tissue-type plasminogen activator [tPA]-Cathflo), not as a part of the institution's standard of care for patency management, in current catheter within 30 days of randomization.
  6. Any participant with unstable arrhythmia, defined as presence of hemodynamic instability within a month prior to the baseline assessment.
  7. Any participant using any type of antimicrobial-coated or heparin-coated catheter.
  8. Any participant with documented chronic bleeding diathesis, active or recurrent bleeding within 1 month prior to randomization.
  9. Any participant with a congenitally lethal condition or a of less than 6 months.
  10. Any participant with documented history of an atrial thrombus or known hypercoagulable state.
  11. Any participant with an open, non-healing skin ulcer.
  12. Any participant who has received an hematopoietic stem cell transplant within the last year.
  13. Any participant with neutropenia with an \<500 cells/μL
  14. Any participant with current requirement for systemic chemotherapy and or and absolute neutrophil count \<500 cells/μL that occured in the past 4 weeks.
  15. Any participant with known allergies or absolute to citrate, taurolidine, pork products, or heparin or a history of heparin-induced thrombocytopenia.
  16. Any participant taking other medication with known systemic drug interaction with citrate, taurolidine or heparin.
  17. Any participant anticipating receiving an intestinal transplant within 90 days. Participants can be on a transplant list but a participant with a known or anticipated transplant date within 90 days of study entry should be excluded from study participation. A participant who may receive an intestinal transplant >90 days of study entry may remain on the study as long as they continue to receive TPN.
  18. Any participant who is pregnant or lactating.
  19. Any participant receiving continuous TPN (infusion over 24 hours).
  20. Any participant with any medical conditions that render them unable to, or unlikely to complete the study or would interfere with optimal participation in the study or produce significant risk to participant.
  21. Any participants who are participating in another interventional clinical study or planning/anticipating participating in another interventional clinical study, except for non-pharmacological research studies.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    DefenCath®

    Drug: (taurolidine and heparin) catheter lock solution

  • Active comparator
    Control

    Drug: Heparin

Interventions

  • Drug(taurolidine and heparin) catheter lock solution

    for central venous catheter installation use

  • Heparin

06

What researchers measure

Primary outcomes

  1. Comparison between treatment groups of proportion of participants who experience a Central Line-Associated Bloodstream Infections (CLABSI) within 12 months of the start of the study

    The proportion of participants who remain infection-free in the treatment groups will be compared, censoring participants who do not experience a CLABSI, but fail to complete the 12-month follow-up period of the study.

    Time frame: Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)

Secondary outcomes

  1. Incidence of AEs, SAEs, treatment-emergent adverse events (TEAEs)

    Compare the safety profile of DefenCath for use as a Catheter Lock Solution (CLS) in adult and adolescent participants receiving Total Parenteral Nutrition (TPN) through a Central Venous Catheter (CVC) to the control of heparin CLS

    Time frame: Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)

  2. Incidence of changes in laboratory evaluations, vital signs, or physical exam findings

    Compare the safety profile of DefenCath for use as a CLS in adult and adolescent participants receiving TPN through a CVC to the control of heparin CLS

    Time frame: Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)

07

Study locations

22 of 24 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Sharibg if protocol and ICF, pending FDA approval of this indication

Supporting information: Study protocol, Informed consent form

Time frame: Pending FDA Approval

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jan 2028, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2025
First posted
Feb 12, 2025
StartActual
May 14, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • Loyola University Medical Center · Maywood, United States
  • NYU Grossman School of Medicine · New York, United States
Sep 25, 2026
Eligibility
Minimum age 18 Years→12 Years; 12 criteria edited, 2 added, 8 removed
What changed in the criteria
  • EditedParticipants who are resident within the US and Türkiyestudy site's country.
  • EditedParticipants who are male or female, aged ≥1812 years at the time of consent.
  • RemovedParticipants must sign and provide informed consent.
  • AddedParticipants must sign and provide informed consent. For adolescent participants or participants that require a legal representative, written informed consent will be obtained from the study participant's legal guardian or legal representative and the assent from the participant when applicable. All legal guardians and representatives should be fully informed, and participants should be informed to the fullest extent possible about the study using language and terms they are able to understand.
  • EditedParticipants who have a permanent tunneled/non-tunneled CVC or permanent peripherally inserted central catheter (PICC) made of silicone or polyurethane, which has been in place for at least 7 days prior to enrollment.
  • EditedParticipants who require long-term (>6 months3 Months) TPN based on the investigator assessments.
  • EditedAny participant unable or not willing to sign inform consent or, in the case of adolescents, not willing to provide assent.
  • EditedAny participant who has receivedis currently receiving systemic antibiotic within the last 14 daysantibiotics. Topical antibiotics are permitted. Use of metronidazole or rifaximin for treating small intestinal bacterial overgrowth (SIBO) is also permitted.
  • ChangedBefore Any participant with temporary, non-tunneled CVC or temporary PICC.Now Any participant with a secondary CVC in addition to the primary TPN line.
  • EditedAny participant who has received a bone marrowan allogeneic hematopoietic stem cell transplant (allogeneic or autogenic/autologous) within the last year.
  • EditedAny participant with neutropenia with an absolute neutrophil count <1000500 cells/μL
  • RemovedAny participant with current requirement for systemic immunosuppression that would increase risk of infection including, but not limited to:
  • RemovedSteroid use at an equivalent dose of prednisone 20 mg/day anticipated or actual for at least 8 weeks.
  • RemovedSystemic chemotherapy.
  • RemovedMethotrexate dose sufficiently high to suppress white blood cell count (WBC) count below 5,000 cells/μL.
  • RemovedAzathioprine dose greater than 2.5 mg/kg/day.
  • RemovedCalcineurin inhibitors:
  • RemovedCyclosporine dose greater than 8 mg/kg. ii. Tacrolimus dose greater than 0.4 mg/kg. f. Sirolimus dose greater 10 mg/daily.
  • AddedAny participant with current requirement for systemic chemotherapy and or immunosuppression and absolute neutrophil count <500 cells/μL that occured in the past 4 weeks.
  • EditedAny participant with known allergies or absolute contraindications to citrate, taurolidine, pork products, or heparin or a history of heparin-induced thrombocytopenia.
  • EditedAny participant anticipating receiving aan intestinal transplant within 90 days. Participants can be on a transplant list but a participant with a known or anticipated transplant date within 90 days of study entry should be excluded from study participation. A participant who may receive aan intestinal transplant >90 days of study entry may remain on the study as long as they continue to receive TPN.
  • EditedAny participants who are participating in another interventional clinical study or planning/anticipating participating in another interventional clinical study, except for non-pharmacological research studies.
Sep 25, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionComparison between treatment groups of proportion of participants who experience a Central Line-Associated Bloodstream Infections (CLABSI) within 12 months of the start of the study: how it is measured was reworded
Sep 25, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionIncidence of AEs, SAEs, treatment-emergent adverse events (TEAEs): how it is measured was reworded
  • DescriptionIncidence of changes in laboratory evaluations, vital signs, or physical exam findings: how it is measured was reworded
Sep 25, 2026
Title
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    2 sites added
    Show 2 added (2 United States)
    • Loyola University Medical Center · Maywood, United States
    • NYU Grossman School of Medicine · New York, United States
    Eligibility Minimum age 18 Years→12 Years; 12 criteria edited, 2 added, 8 removed
    What changed in the criteria
    • EditedParticipants who are resident within the US and Türkiyestudy site's country.
    • EditedParticipants who are male or female, aged ≥1812 years at the time of consent.
    • RemovedParticipants must sign and provide informed consent.
    • AddedParticipants must sign and provide informed consent. For adolescent participants or participants that require a legal representative, written informed consent will be obtained from the study participant's legal guardian or legal representative and the assent from the participant when applicable. All legal guardians and representatives should be fully informed, and participants should be informed to the fullest extent possible about the study using language and terms they are able to understand.
    • EditedParticipants who have a permanent tunneled/non-tunneled CVC or permanent peripherally inserted central catheter (PICC) made of silicone or polyurethane, which has been in place for at least 7 days prior to enrollment.
    • EditedParticipants who require long-term (>6 months3 Months) TPN based on the investigator assessments.
    • EditedAny participant unable or not willing to sign inform consent or, in the case of adolescents, not willing to provide assent.
    • EditedAny participant who has receivedis currently receiving systemic antibiotic within the last 14 daysantibiotics. Topical antibiotics are permitted. Use of metronidazole or rifaximin for treating small intestinal bacterial overgrowth (SIBO) is also permitted.
    • ChangedBefore Any participant with temporary, non-tunneled CVC or temporary PICC.Now Any participant with a secondary CVC in addition to the primary TPN line.
    • EditedAny participant who has received a bone marrowan allogeneic hematopoietic stem cell transplant (allogeneic or autogenic/autologous) within the last year.
    • EditedAny participant with neutropenia with an absolute neutrophil count <1000500 cells/μL
    • RemovedAny participant with current requirement for systemic immunosuppression that would increase risk of infection including, but not limited to:
    • RemovedSteroid use at an equivalent dose of prednisone 20 mg/day anticipated or actual for at least 8 weeks.
    • RemovedSystemic chemotherapy.
    • RemovedMethotrexate dose sufficiently high to suppress white blood cell count (WBC) count below 5,000 cells/μL.
    • RemovedAzathioprine dose greater than 2.5 mg/kg/day.
    • RemovedCalcineurin inhibitors:
    • RemovedCyclosporine dose greater than 8 mg/kg. ii. Tacrolimus dose greater than 0.4 mg/kg. f. Sirolimus dose greater 10 mg/daily.
    • AddedAny participant with current requirement for systemic chemotherapy and or immunosuppression and absolute neutrophil count <500 cells/μL that occured in the past 4 weeks.
    • EditedAny participant with known allergies or absolute contraindications to citrate, taurolidine, pork products, or heparin or a history of heparin-induced thrombocytopenia.
    • EditedAny participant anticipating receiving aan intestinal transplant within 90 days. Participants can be on a transplant list but a participant with a known or anticipated transplant date within 90 days of study entry should be excluded from study participation. A participant who may receive aan intestinal transplant >90 days of study entry may remain on the study as long as they continue to receive TPN.
    • EditedAny participants who are participating in another interventional clinical study or planning/anticipating participating in another interventional clinical study, except for non-pharmacological research studies.
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionComparison between treatment groups of proportion of participants who experience a Central Line-Associated Bloodstream Infections (CLABSI) within 12 months of the start of the study: how it is measured was reworded
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionIncidence of AEs, SAEs, treatment-emergent adverse events (TEAEs): how it is measured was reworded
    • DescriptionIncidence of changes in laboratory evaluations, vital signs, or physical exam findings: how it is measured was reworded
    Title Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06822426
Responsible party
Sponsor
First posted
Feb 12, 2025
Start date
May 14, 2025
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Sep 25, 2026

Study contacts

Liz Hurlburt, Chief Clinical Strategy & Operations Officer
Contact
lhurlburt@cormedix.com
908-517-9500

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion